Pelage Pharmaceuticals, Inc. is a biotechnology company developing novel drugs to promote hair health.
Market:
Currently, 400 million people, both men and women, suffer from Alopecia worldwide. There are only two FDA-approved medications for treating non-scarring Alopecia, Propecia and Rogaine (Minoxidil). Propecia is associated with adverse side effects and neither drug is very effective. More than $7 billion is being spent on hair loss treatments annually.
Technology:
Pelage’s proprietary small molecules are the first to target hair follicle stem cell metabolism causing their activation.Advantages:
- Activates quiescent hair follicle stem cells
- Small molecules access the hair follicles when applies to the scalp
- No need for implants, injections or oral treatments
Patents:
- Pelage has licensed rights from the University of California to pending patent applications covering the technology.
Development Stage:
- Pre-clinical
Select Publications:
Contact:
Email: info@pelagepharma.comPortfolio Companies
- Active Membranes, LLC.
- Avesta76 Therapeutics
- Capacity Bio
- CDR3 Therapeutics, Inc.
- Dalton Bioanalytics
- EarlyDx
- Forcyte Biotechnologies
- ImmunoVec
- Lactation Lab
- Lookin, Inc.
- Partillion Bioscience Corporation
- Pelage Pharmaceuticals
- Pluto Immunotherapeutics
- Scarless Laboratories
- Sorriso Pharmaceuticals
- Symphony Biosciences
- Vault Pharma
- ViBo Health
- Westwood Bioscience